AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 70.55% Potential Upside Amidst a Strong Buy Consensus
AngioDynamics, Inc. (NASDAQ: ANGO), a prominent player in the healthcare sector specializing in medical instruments and ...
Model output · Signal date 2026-10-16
Angiodynamics Inc (ANGO) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Top 35%
of 5172 stocks scored
Rank correlation · 90D
49.0%
Spearman, 357 dates
Market Cap
$473M
small-cap · #46 of 60 peers
Summary
Angiodynamics Inc (ANGO) stock forecast summary
Our AI ranks Angiodynamics Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Angiodynamics Inc is a small-cap company with a market capitalization of $473M. It ranks number 46 by market capitalization among the 60 Surgical & Medical Instruments & Apparatus issuers in our coverage with a current forecast.
For ANGO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 49.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 39.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ANGO included.
Follow ANGO freePrice
ANGO price chart and AI forecast
Cross-section · 2026-10-16
How ANGO ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-08-31
Angiodynamics Inc (ANGO) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Surgical & Medical Instruments & Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | ANGO | Rank |
|---|---|---|
| Market Cap | $473M | 46/60 |
| P/B Ratio | 2.88x | 40/55 |
| EPS | $-0.79 | – |
| Book Value/Share | $3.90 | – |
| Revenue/Share | $7.74 | – |
| FCF/Share | $0.03 | – |
Profitability & Margins
| Metric | ANGO | Rank |
|---|---|---|
| ROE | -23.2% | 26/41 |
| ROA | -15.7% | 29/44 |
| ROIC | -20.1% | 40/53 |
| Gross Margin | 55.6% | 39/53 |
| Operating Margin | -11.0% | 37/54 |
| Net Margin | -11.4% | 25/43 |
| EBT Margin | -9.8% | 36/54 |
| Tax Rate | -0.5% | – |
Financial Health
| Metric | ANGO | Rank |
|---|---|---|
| Current Ratio | 2.40x | 44/59 |
| Quick Ratio | 1.48x | 40/55 |
| D/E Ratio | 0.48x | 32/56 |
| Financial Leverage | 1.48x | 31/54 |
| Interest Coverage | 25.5x | 5/48 |
| Working Capital | $83M | 47/59 |
Cash Flow
| Metric | ANGO | Rank |
|---|---|---|
| Operating Cash Flow | $4M | 35/55 |
| Free Cash Flow | $1M | 26/50 |
| Capital Spending | -$2M | 10/50 |
| FCF/Sales | 0.4% | 26/49 |
| CapEx/Sales | 0.7% | 44/49 |
Operational Efficiency
| Metric | ANGO | Rank |
|---|---|---|
| Asset Turnover | 1.34x | 3/50 |
| Receivables Turnover | 7.2x | 14/51 |
| Inventory Turnover | 2.6x | 16/51 |
| Fixed Assets Turnover | 11.7x | 13/52 |
| Days Sales Outstanding | 50 days | 38/51 |
| Days Inventory | 139 days | 36/51 |
| Payables Period | 67 days | 21/46 |
| Cash Conversion Cycle | 122 days | 28/42 |
Income Statement
| Metric | ANGO | Rank |
|---|---|---|
| Total Revenue | $325M | 34/52 |
| Operating Income | -$37M | 38/55 |
| Net Income | -$38M | 27/44 |
| R&D Expense | $31M | 36/53 |
| SG&A Expense | $187M | 36/53 |
| Cost of Goods Sold | $144M | 28/53 |
Dividend & Shareholder Information
| Metric | ANGO | Rank |
|---|---|---|
| Shares Outstanding | 42M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $143M | 59.1% of assets |
| Cash & Short-term Investments | $34M | 14.0% of assets |
| Accounts Receivable | $45M | 18.6% of assets |
| Inventory | $55M | 22.7% of assets |
| Total Liabilities | $78M | 32.2% of assets |
| Short-term Debt | $33M | 13.7% of assets |
Quarterly Financial Reports
ANGO quarterly financials and insider trading
Industry Peers · Surgical & Medical Instruments & Apparatus
Angiodynamics Inc (ANGO) industry peers
Companies classified under the same SEC industry code as Angiodynamics Inc (Surgical & Medical Instruments & Apparatus): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ANGO Angiodynamics Inc | ▲ | $473M |
| SYK Stryker Corp | ▼ | $113.02B |
| MMM 3m Co | ▶ | $84.97B |
| BSX Boston Scientific Corp | ▼ | $64.33B |
| BDX Becton Dickinson & Co | ▼ | $52.23B |
| MDLN Medline Inc. | ▶ | $47.28B |
| RMD Resmed Inc | ▼ | $34.47B |
| DXCM Dexcom Inc | ▼ | $32.47B |
| WST West Pharmaceutical Services Inc | ▼ | $27.03B |
| SOLV Solventum Corp | ▼ | $14.61B |
| BAX Baxter International Inc | ▼ | $13.07B |
| PEN Penumbra Inc | ▼ | $12.64B |
| GMED Globus Medical Inc | ▼ | $10.30B |
| PODD Insulet Corp | ▼ | $9.79B |
| GKOS Glaukos Corp | ▲ | $9.72B |
| TFX Teleflex Inc | ▼ | $5.53B |
| HAE Haemonetics Corp | ▶ | $5.38B |
| MMSI Merit Medical Systems Inc | ▼ | $5.33B |
| STVN Stevanato Group S.P.A. | ▲ | $5.16B |
| MMED Minimed Group, Inc. | ▲ | $4.92B |
| HTFL Heartflow, Inc. | ▲ | $4.20B |
| ICUI Icu Medical Inc/De | ▼ | $4.08B |
| IRTC Irhythm Holdings, Inc. | ▼ | $3.58B |
| PLSE Pulse Biosciences, Inc. | ▲ | $3.17B |
| ATRC Atricure, Inc. | ▲ | $2.85B |
| UFPT Ufp Technologies Inc | ▼ | $2.26B |
| INSP Inspire Medical Systems, Inc. | ▲ | $1.99B |
| LMAT Lemaitre Vascular Inc | ▶ | $1.85B |
| NVCR Novocure Ltd | ▲ | $1.64B |
| KMTS Kestra Medical Technologies, Ltd. | ▲ | $1.62B |
| ATEC Alphatec Holdings, Inc. | ▲ | $1.62B |
| TNDM Tandem Diabetes Care Inc | ▲ | $1.13B |
| IRMD Iradimed Corp | ▶ | $1.13B |
| DRTS Alpha Tau Medical Ltd. | ▶ | $1.08B |
| AORT Artivion, Inc. | ▶ | $1.06B |
| IART Integra Lifesciences Holdings Corp | ▶ | $1.03B |
| PRCT Procept Biorobotics Corp | ▲ | $1.01B |
| BVS Bioventus Inc. | ▶ | $908M |
| SIBN Si-Bone, Inc. | ▶ | $882M |
| BBNX Beta Bionics, Inc. | ▲ | $863M |
| SGP Spyglass Pharma, Inc. | ▶ | $803M |
| MDXG Mimedx Group, Inc. | ▲ | $646M |
| KIDS Orthopediatrics Corp | ▶ | $573M |
| SSII Ss Innovations International, Inc. | ▲ | $517M |
| TCMD Tactile Systems Technology Inc | ▼ | $510M |
| DCTH Delcath Systems, Inc. | ▲ | $497M |
| SGHT Sight Sciences, Inc. | ▲ | $456M |
| BWAY Brainsway Ltd. | ▶ | $448M |
| CERS Cerus Corp | ▶ | $439M |
| NPCE Neuropace Inc | ▶ | $420M |
| RCEL Avita Medical, Inc. | ▲ | $403M |
| OFIX Orthofix Medical Inc. | ▼ | $382M |
| CARL Carlsmed, Inc. | ▲ | $366M |
| EMBC Embecta Corp. | ▶ | $355M |
| OBIO Orchestra Biomed Holdings, Inc. | ▲ | $328M |
| CLPT Clearpoint Neuro, Inc. | ▲ | $277M |
| MOBI Mobia Medical, Inc. | ▼ | $269M |
| ANIK Anika Therapeutics, Inc. | ▶ | $267M |
| TMCI Treace Medical Concepts, Inc. | ▲ | $252M |
| OSUR Orasure Technologies Inc | ▲ | $249M |
Where ANGO sits on the market map
Industrial Applications and Services · Surgical & Medical Instruments & Apparatus
News
Angiodynamics Inc (ANGO) stock news
AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist
AlphaVac, Auryon, NanoKnife growth vs execution risk and margin swings. Click for this updated look at ANGO prospects.
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, ...
FAQ
Angiodynamics Inc (ANGO) stock forecast FAQ
What is the Angiodynamics Inc (ANGO) stock forecast?
Our AI ranks Angiodynamics Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Angiodynamics Inc stock predictions?
For ANGO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 49.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 39.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Angiodynamics Inc forecasts updated?
Angiodynamics Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Angiodynamics Inc's industry peers?
60 issuers in our coverage, ANGO included, share the SEC industry code Surgical & Medical Instruments & Apparatus. The largest are: Stryker Corp (SYK), 3m Co (MMM), Boston Scientific Corp (BSX), Becton Dickinson & Co (BDX), Medline Inc. (MDLN), Resmed Inc (RMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.